Harish Hk Murthy, MD
Pulmonary Disease · San Jose
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 34
- 9 carriers
- Offices
- 7
Offices
7 locations · University Healthcare Alliance · Bass Medical Group
Hospitals listed: Good Samaritan Hospital · Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
34 plans · 9 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Murthy’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
34 of 34 plans
| Alignment Health Advantage PPO (PPO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Sutter Advantage +More (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Prime (HMO-POS) | Anthem Blue Cross Partnership Plan | Listed | Oct 3, 2026 |
| Astiva Health C-SNP WOW - NorCal (HMO C-SNP) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Premier Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Savings Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Blue Shield Inspire (HMO) | Blue Shield of California | Listed | Aug 26, 2026 |
| Central Health Classic Care Plan III (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Dual Access Plan (HMO D-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Embrace Care Plan (HMO C-SNP) | Central Health Medicare Plan | Listed, may be out of date | Sep 15, 2025 |
| Central Health Embrace Choice Plan (HMO C-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Valor Care Plan (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Good Samaritan HospitalSan Jose, CAAcute Care Hospital · Proprietary · Has an emergency department · Birthing-friendlyPart of HCA Healthcare, which runs 185 hospitals in 19 statesPatients rate it 2 of 5 · 67% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.337, Oct 2024 – Sep 2025
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Good Samaritan Hospital
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 1 worse of 8 measures. Readmissions: 0 better, 5 the same, 4 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.337 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.75 (0 to 1.67) · 1,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.84 (0.54 to 1.14) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 143.59 (98.7 to 188.49) · 98 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.7 · 45 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 100 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.7 · 270 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.3 · 573 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.6 · 820 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.5 · 482 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.3 · 3,711 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.12 (0 to 0.3) · 8,866 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.01 to 0.38) · 9,051 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.65 (0.74 to 4.56) · 1,929 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.8 (0.21 to 3.39) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.33 (0.88 to 3.78) · 1,836 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.73 (0 to 13.46) · 669 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.58 (3.96 to 11.19) · 654 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.59 (0.13 to 3.04) · 496 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.27 (0 to 0.87) · 7,373 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.1 · 152 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 1.08 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.542 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.484 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.565 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.8 · 327 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 24.2 · 703 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 61.1 · 289 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 36.3 · 665 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 25.4 · 856 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19 · 978 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.3 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 12.3 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 21.2 · 135 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.8 (10.1 to 18.6) · 129 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (0.9 to 1.5) · 531 cases | No different | Jan 2024 – Dec 2024 |
What patients said (704 patients answered, 24% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 2 |
| Quietness | 1 |
| Recommend hospital | 3 |
| Room was "always" clean | 66% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 71% |
| Staff "always" explained | 54% |
| Yes, staff "did" give patients this information | 83% |
| Yes, staff "did" give patients information about help after discharge | 81% |
| Doctors "always" explained things so they could understand | 66% |
| Doctors "always" listened carefully | 69% |
| Doctors "always" treated them with courtesy and respect | 78% |
| Patients who gave a rating of "9" or "10" (high) | 63% |
| Staff "always" explained new medications | 68% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 73% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 38% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 40% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$474,151
Medicare paid this office $474,151 for 1,249 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 848 | $184,561 | $118 |
| Sleep study in sleep lab (6 years or older) | 109 | $75,327 | $673 |
| Sleep study in sleep lab with continuous airway pressure (6 years or older) | 100 | $69,504 | $695 |
| Critical care, first 30-74 minutes | 175 | $58,646 | $184 |
| New patient visit (45+ min) | 211 | $31,853 | $151 |
See all 15 services
| Return visit (30+ min) | 848 | $184,561 | $118 |
| Sleep study in sleep lab (6 years or older) | 109 | $75,327 | $673 |
| Sleep study in sleep lab with continuous airway pressure (6 years or older) | 100 | $69,504 | $695 |
| Critical care, first 30-74 minutes | 175 | $58,646 | $184 |
| New patient visit (45+ min) | 211 | $31,853 | $151 |
| Sleep study including heart rate, breathing, airflow, and effort | 156 | $14,564 | $91 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 98 | $13,907 | $106 |
| Long return visit (40+ min) | 23 | $4,153 | $160 |
| Test to examine how well the lungs exchange gases | 81 | $3,863 | $48 |
| Test for exercise-induced lung stress | 94 | $3,035 | $31 |
| Test to determine lung volumes using gas dilution or washout | 81 | $2,924 | $36 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 81 | $2,458 | $30 |
| Short return visit (20+ min) | 35 | $1,998 | $55 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 19 | $1,852 | $69 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 64 | $1,401 | $21 |
Who their Medicare patients are
1,249 Original Medicare patients in 2024. Average age 76 · Under 65 3% · 85 and older 16% · Women 48% · Also on Medicaid 10% · Health risk score 1.60. At or below the middle of the specialty; the typical pulmonary disease clinician is at 2.13.
Conditions among them: High blood pressure 75% · Coronary heart disease 48% · Diabetes 41% · Atrial fibrillation 32% · Heart failure 29% · Chronic kidney disease 28% · COPD 27% · Depression 22% · Cancer 18% · Stroke 16% · Dementia 12%.
The office billed $2,013,221, Medicare allowed $619,709 and paid $474,151; for 3,141 services of 27 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 1,249 | 3,141 | 76 | 1.60 | $2,013,221 | $474,151 |
| 2023 | 1,148 | 3,527 | 76 | 1.55 | $1,980,615 | $495,591 |
| 2022 | 1,130 | 3,711 | 76 | 1.46 | $2,029,340 | $506,485 |
| 2021 | 1,102 | 3,290 | 77 | 1.56 | $1,854,164 | $519,430 |
| 2020 | 1,166 | 3,852 | 76 | 1.75 | $1,943,685 | $575,088 |
| 2019 | 1,213 | 4,131 | 76 | 1.66 | $1,667,444 | $541,807 |
| 2018 | 1,005 | 3,217 | 76 | 1.71 | $804,506 | $331,166 |
| 2017 | 924 | 2,910 | 76 | 1.85 | $708,049 | $289,744 |
| 2016 | 965 | 3,266 | 76 | 1.95 | $747,216 | $320,667 |
| 2015 | 903 | 3,124 | 75 | 1.87 | $711,834 | $320,662 |
| 2014 | 813 | 3,229 | 76 | 1.83 | $791,818 | $328,153 |
| 2013 | 800 | 3,060 | 75 | 1.78 | $726,043 | $302,212 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 17 services
| Return visit (30+ min) | 736 | $158,052 | $115 |
| Sleep study in sleep lab with continuous airway pressure (6 years or older) | 114 | $79,742 | $693 |
| Sleep study in sleep lab (6 years or older) | 107 | $71,579 | $663 |
| Critical care, first 30-74 minutes | 145 | $64,437 | $192 |
| Short return visit (20+ min) | 345 | $32,741 | $83 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 96 | $18,539 | $110 |
| Long return visit (40+ min) | 51 | $11,029 | $160 |
| Telephone medical discussion with physician, 21-30 minutes | 85 | $10,792 | $109 |
| Test to examine how well the lungs exchange gases | 168 | $9,960 | $56 |
| Sleep study including heart rate, breathing, airflow, and effort | 90 | $8,575 | $93 |
| Test to determine lung volumes using gas dilution or washout | 166 | $7,101 | $41 |
| New patient visit (45+ min) | 46 | $6,340 | $138 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 165 | $6,031 | $35 |
| Test for exercise-induced lung stress | 93 | $3,130 | $32 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 30 | $2,918 | $73 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 18 | $813 | $45 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 16 | $419 | $25 |
2022: 21 services
| Return visit (30+ min) | 606 | $136,670 | $113 |
| Sleep study in sleep lab with continuous airway pressure (6 years or older) | 131 | $93,304 | $681 |
| Critical care, first 30-74 minutes | 149 | $69,603 | $194 |
| Sleep study in sleep lab (6 years or older) | 94 | $62,401 | $643 |
| Short return visit (20+ min) | 308 | $27,412 | $76 |
| New patient visit (45+ min) | 149 | $20,923 | $140 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 105 | $18,106 | $93 |
| Long return visit (40+ min) | 78 | $17,264 | $160 |
| Test to examine how well the lungs exchange gases | 199 | $12,433 | $60 |
| Test to determine lung volumes using gas dilution or washout | 206 | $9,001 | $41 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 204 | $7,686 | $36 |
| Telephone medical discussion with physician, 21-30 minutes | 65 | $7,508 | $104 |
| New patient visit (60+ min) | 31 | $6,221 | $201 |
| Test for exercise-induced lung stress | 145 | $5,090 | $32 |
| Sleep study including heart rate, breathing, airflow, and effort | 30 | $2,831 | $94 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 11 | $1,987 | $181 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 21 | $1,627 | $65 |
| Telephone medical discussion with physician, 11-20 minutes | 21 | $1,368 | $62 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 39 | $863 | $22 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 19 | $665 | $35 |
| Short return visit | 13 | $522 | $40 |
2021: 21 services
| Return visit (30+ min) | 533 | $125,640 | $120 |
| Sleep study in sleep lab with continuous airway pressure (6 years or older) | 140 | $100,155 | $700 |
| Critical care, first 30-74 minutes | 193 | $99,324 | $200 |
| Sleep study in sleep lab (6 years or older) | 78 | $52,644 | $675 |
| Short return visit (20+ min) | 210 | $22,789 | $84 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 123 | $19,738 | $96 |
| New patient visit (45+ min) | 107 | $15,959 | $149 |
| Telephone medical discussion with physician, 21-30 minutes | 111 | $15,866 | $113 |
| Test to examine how well the lungs exchange gases | 212 | $12,901 | $60 |
| New patient visit (60+ min) | 62 | $12,522 | $202 |
| Long return visit (40+ min) | 52 | $11,284 | $168 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 224 | $10,164 | $45 |
| Telephone medical discussion with physician, 11-20 minutes | 48 | $4,435 | $87 |
| Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | 19 | $4,335 | $228 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 13 | $2,423 | $186 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 20 | $2,274 | $67 |
| Sleep study including heart rate, breathing, airflow, and effort | 15 | $1,594 | $106 |
| Hospital discharge day management, more than 30 minutes | 12 | $1,209 | $101 |
| Test for exercise-induced lung stress | 28 | $1,035 | $33 |
| Test to determine lung volumes using gas dilution or washout | 13 | $585 | $45 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 14 | $499 | $36 |
2020: 21 services
| Critical care, first 30-74 minutes | 270 | $174,158 | $199 |
| Return visit (30+ min) | 501 | $100,447 | $98 |
| Sleep study in sleep lab with continuous airway pressure (6 years or older) | 131 | $91,917 | $681 |
| Sleep study in sleep lab (6 years or older) | 89 | $58,638 | $652 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 182 | $35,195 | $96 |
| Short return visit (20+ min) | 250 | $23,220 | $65 |
| New patient visit (45+ min) | 157 | $21,406 | $136 |
| Telephone medical discussion with physician, 21-30 minutes | 87 | $11,517 | $106 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 142 | $9,258 | $53 |
| Test to examine how well the lungs exchange gases | 144 | $8,666 | $50 |
| Long return visit (40+ min) | 35 | $6,695 | $139 |
| New patient visit (60+ min) | 35 | $6,656 | $190 |
| Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | 25 | $5,938 | $220 |
| Telephone medical discussion with physician, 11-20 minutes | 70 | $5,140 | $69 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 17 | $3,201 | $188 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 38 | $3,088 | $67 |
| Critical care, each additional 30 minutes | 20 | $2,649 | $102 |
| Hospital discharge day management, more than 30 minutes | 12 | $1,216 | $101 |
| Test to determine lung volumes using gas dilution or washout | 20 | $822 | $41 |
| Test for exercise-induced lung stress | 19 | $541 | $27 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 13 | $507 | $36 |
2019: 19 services
| Critical care, first 30-74 minutes | 258 | $123,422 | $192 |
| Return visit (30+ min) | 551 | $117,899 | $98 |
| Sleep study in sleep lab with continuous airway pressure (6 years or older) | 92 | $62,838 | $676 |
| Sleep study in sleep lab (6 years or older) | 92 | $59,776 | $643 |
| New patient visit (45+ min) | 270 | $38,435 | $142 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 216 | $34,322 | $93 |
| Short return visit (20+ min) | 336 | $33,255 | $66 |
| Long return visit (40+ min) | 57 | $11,530 | $136 |
| Test to examine how well the lungs exchange gases | 168 | $9,915 | $56 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 156 | $9,364 | $58 |
| New patient visit (60+ min) | 44 | $7,855 | $179 |
| Test to determine lung volumes using gas dilution or washout | 167 | $7,404 | $42 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 60 | $5,837 | $64 |
| Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | 18 | $3,991 | $222 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 16 | $2,953 | $174 |
| Sleep study including heart rate, breathing, airflow, and effort | 19 | $2,620 | $131 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 35 | $1,941 | $35 |
| Hospital discharge day management, more than 30 minutes | 18 | $1,791 | $94 |
| Test for exercise-induced lung stress | 54 | $1,723 | $30 |
2018: 13 services
| Return visit (30+ min) | 463 | $95,985 | $96 |
| Critical care, first 30-74 minutes | 208 | $79,628 | $193 |
| Short return visit (20+ min) | 305 | $32,270 | $65 |
| New patient visit (45+ min) | 184 | $26,385 | $143 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 130 | $20,373 | $92 |
| Long return visit (40+ min) | 73 | $16,983 | $131 |
| New patient visit (60+ min) | 90 | $16,591 | $184 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 149 | $9,419 | $62 |
| Test to examine how well the lungs exchange gases | 154 | $8,911 | $57 |
| Sleep study including heart rate, breathing, airflow, and effort | 43 | $7,980 | $170 |
| Test to determine lung volumes using gas dilution or washout | 154 | $7,054 | $45 |
| Test for exercise-induced lung stress | 78 | $2,749 | $32 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 21 | $2,223 | $65 |
2017: 14 services
| Return visit (30+ min) | 365 | $77,481 | $94 |
| Critical care, first 30-74 minutes | 204 | $73,143 | $186 |
| Short return visit (20+ min) | 246 | $24,531 | $64 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 126 | $24,393 | $90 |
| New patient visit (45+ min) | 147 | $20,320 | $138 |
| Long return visit (40+ min) | 78 | $16,614 | $124 |
| New patient visit (60+ min) | 87 | $15,228 | $175 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 180 | $9,739 | $52 |
| Test to examine how well the lungs exchange gases | 181 | $9,159 | $49 |
| Sleep study including heart rate, breathing, airflow, and effort | 41 | $6,897 | $157 |
| Test to determine lung volumes using gas dilution or washout | 122 | $4,232 | $34 |
| Pulmonary exercise testing | 45 | $2,311 | $47 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 15 | $1,005 | $59 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 13 | $542 | $32 |
2016: 16 services
| Critical care, first 30-74 minutes | 284 | $122,192 | $185 |
| Return visit (30+ min) | 306 | $55,267 | $90 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 186 | $43,309 | $88 |
| New patient visit (45+ min) | 106 | $14,429 | $136 |
| Long return visit (40+ min) | 62 | $13,476 | $124 |
| Short return visit (20+ min) | 146 | $13,359 | $64 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 232 | $12,067 | $49 |
| Test to examine how well the lungs exchange gases | 236 | $11,494 | $46 |
| Test to determine lung volumes using gas dilution or washout | 236 | $7,912 | $32 |
| Sleep study including heart rate, breathing, airflow, and effort | 38 | $6,482 | $154 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 55 | $6,360 | $62 |
| New patient visit (60+ min) | 21 | $3,787 | $180 |
| Hospital discharge day management, more than 30 minutes | 21 | $1,961 | $93 |
| Pulmonary exercise testing | 38 | $1,867 | $42 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 30 | $1,374 | $34 |
| Hospital discharge day management, 30 minutes or less | 11 | $694 | $63 |
2015: 15 services
| Critical care, first 30-74 minutes | 259 | $114,661 | $193 |
| Return visit (30+ min) | 331 | $67,486 | $95 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 214 | $49,093 | $92 |
| New patient visit (45+ min) | 115 | $16,560 | $144 |
| Short return visit (20+ min) | 126 | $10,557 | $63 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 82 | $9,626 | $64 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 169 | $9,240 | $52 |
| Test to examine how well the lungs exchange gases | 170 | $8,718 | $49 |
| Long return visit (40+ min) | 35 | $7,054 | $128 |
| Sleep study including heart rate, breathing, airflow, and effort | 40 | $6,710 | $164 |
| Test to determine lung volumes using gas dilution or washout | 170 | $5,950 | $33 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 61 | $2,670 | $34 |
| Pulmonary exercise testing | 44 | $1,951 | $43 |
| Hospital discharge day management, more than 30 minutes | 18 | $1,828 | $96 |
| Emergent insertion of breathing tube into windpipe using an endoscope | 11 | $1,128 | $94 |
2014: 19 services
| Critical care, first 30-74 minutes | 228 | $112,902 | $195 |
| Return visit (30+ min) | 294 | $64,829 | $93 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 222 | $52,913 | $92 |
| Short return visit (20+ min) | 207 | $17,598 | $62 |
| New patient visit (45+ min) | 124 | $17,130 | $138 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 119 | $16,758 | $64 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 118 | $6,578 | $53 |
| Sleep study including heart rate, breathing, airflow, and effort | 35 | $6,466 | $170 |
| Test to examine how well the lungs exchange gases | 118 | $6,138 | $50 |
| Test to determine lung volumes using gas dilution or washout | 114 | $4,184 | $35 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 69 | $2,984 | $35 |
| Hospital discharge day management, more than 30 minutes | 28 | $2,703 | $97 |
| Long return visit (40+ min) | 17 | $2,685 | $128 |
| Emergent insertion of breathing tube into windpipe using an endoscope | 18 | $2,101 | $96 |
| New patient visit (60+ min) | 11 | $2,072 | $188 |
| Pulmonary exercise testing | 29 | $1,531 | $46 |
| Insertion of non-tunneled central venous tube for infusion (5 years or older) | 11 | $1,174 | $107 |
| Hospital discharge day management, 30 minutes or less | 18 | $1,168 | $65 |
| Smoking and tobacco use intensive counseling, 4-10 minutes | 13 | $216 | $13 |
2013: 18 services
| Critical care, first 30-74 minutes | 191 | $81,123 | $190 |
| Return visit (30+ min) | 287 | $70,238 | $93 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 219 | $52,464 | $90 |
| Short return visit (20+ min) | 208 | $21,313 | $64 |
| New patient visit (45+ min) | 118 | $17,171 | $146 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 105 | $13,103 | $62 |
| Sleep study including heart rate, breathing, airflow, and effort | 51 | $9,790 | $178 |
| Test to examine how well the lungs exchange gases | 110 | $6,524 | $59 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 112 | $6,508 | $58 |
| Test to determine lung volumes using gas dilution or washout | 106 | $4,437 | $41 |
| New patient visit (60+ min) | 18 | $3,105 | $172 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 15 | $2,642 | $176 |
| Hospital discharge day management, more than 30 minutes | 23 | $2,278 | $95 |
| Long return visit (40+ min) | 15 | $2,251 | $132 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 49 | $2,186 | $34 |
| Insertion of non-tunneled central venous tube for infusion (5 years or older) | 14 | $1,655 | $103 |
| Pulmonary exercise testing | 26 | $1,629 | $51 |
| Smoking and tobacco use intensive counseling, 4-10 minutes | 19 | $243 | $12 |
Medicaid work
$0 in 2022
Medicaid paid $0 for 69 billed services this clinician did in 2022, up to 16 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Polysomnography; age 6 years or older, sleep staging with 4 or more additional parameters of sleep, with initiation of continuous positive airway pressure therapy or bilevel ventilation, attended by a technologist | 13 | $0 |
| New patient visit (30+ min) | 12 | $0 |
| New patient visit (45+ min) | 30 | $0 |
| Return visit (30+ min) | 14 | $0 |
| 2022 | 69 | 4 | 16 | $0 |
Drugs they prescribed that Part D paid
$752,772
Pharmacies billed $752,772 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 1,702) in 2024. At or below the middle of the specialty; the typical pulmonary disease clinician is at 0%.
947 generic and 755 brand-name prescriptions · $752,772 in drug cost · 55 antibiotic prescriptions to 35 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Trelegy Ellipta | 295 | $307,965 | $1,044 |
| Ofev | 12 | $174,146 | $14,512 |
| Breo Ellipta | 164 | $106,425 | $649 |
| Spiriva Handihaler | 18 | $25,759 | $1,431 |
| Spiriva Respimat | 21 | $21,602 | $1,029 |
See all 26 drugs
| Trelegy Ellipta | 295 | $307,965 | $1,044 |
| Ofev | 12 | $174,146 | $14,512 |
| Breo Ellipta | 164 | $106,425 | $649 |
| Spiriva Handihaler | 18 | $25,759 | $1,431 |
| Spiriva Respimat | 21 | $21,602 | $1,029 |
| Incruse Ellipta | 28 | $17,394 | $621 |
| Combivent Respimat | 26 | $13,236 | $509 |
| Symbicort | 24 | $13,216 | $551 |
| Wixela Inhub | 50 | $7,229 | $145 |
| Montelukast | 385 | $6,138 | $16 |
| Albuterol Sulfate Hfa | 156 | $4,513 | $29 |
| Fluticasone-Salmeterol | 30 | $4,321 | $144 |
| Arnuity Ellipta | 11 | $2,709 | $246 |
| Azelastine | 52 | $1,494 | $29 |
| Clarithromycin | 38 | $988 | $26 |
| Ipratropium | 25 | $934 | $37 |
| Temazepam | 12 | $600 | $50 |
| Pramipexole Dihydrochloride | 32 | $555 | $17 |
| Modafinil | 12 | $433 | $36 |
| Prednisone | 63 | $333 | $5 |
| Omeprazole | 19 | $301 | $16 |
| Fluticasone Propionate | 11 | $211 | $19 |
| Zolpidem | 11 | $116 | $11 |
| Pantoprazole | 17 | $108 | $6 |
| Eszopiclone | 30 | $105 | $3 |
| Trazodone | 22 | $93 | $4 |
Year by year
| 2024 | 1,702 | 334 | 0% (0) | 44% | $752,772 |
| 2023 | 1,912 | 343 | None | None | $899,089 |
| 2022 | 2,066 | 357 | 0% (0) | None | $913,457 |
| 2021 | 2,122 | 346 | 0% (0) | 52% | $933,807 |
| 2020 | 1,815 | 316 | 0% (0) | 52% | $627,641 |
| 2019 | 1,836 | 342 | None | 47% | $592,434 |
| 2018 | 1,431 | 265 | None | 49% | $468,743 |
| 2017 | 1,281 | 204 | None | 47% | $315,523 |
| 2016 | 1,175 | 169 | None | 50% | $299,601 |
| 2015 | 1,501 | 177 | None | 51% | $421,105 |
| 2014 | 1,848 | 198 | None | 54% | $599,504 |
| 2013 | 1,699 | 183 | 1% (11) | 55% | $485,013 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 27 drugs
| Trelegy Ellipta | 285 | $282,230 | $990 |
| Breo Ellipta | 191 | $143,260 | $750 |
| Symbicort | 73 | $59,406 | $814 |
| Spiriva Handihaler | 43 | $51,338 | $1,194 |
| Spiriva Respimat | 40 | $42,414 | $1,060 |
| Advair Diskus | 49 | $39,677 | $810 |
| Incruse Ellipta | 30 | $17,059 | $569 |
| Anoro Ellipta | 20 | $15,070 | $754 |
| Combivent Respimat | 23 | $14,222 | $618 |
| Montelukast | 431 | $8,387 | $19 |
| Albuterol Sulfate Hfa | 137 | $5,789 | $42 |
| Bevespi Aerosphere | 13 | $5,758 | $443 |
| Wixela Inhub | 15 | $5,662 | $377 |
| Dulera | 14 | $5,187 | $371 |
| Ipratropium | 65 | $2,171 | $33 |
| Ventolin Hfa | 23 | $2,133 | $93 |
| Azelastine | 38 | $1,727 | $45 |
| Clarithromycin | 36 | $1,480 | $41 |
| Azithromycin | 15 | $905 | $60 |
| Pramipexole Dihydrochloride | 28 | $433 | $15 |
| Prednisone | 70 | $317 | $5 |
| Pantoprazole | 21 | $277 | $13 |
| Omeprazole | 21 | $212 | $10 |
| Fluticasone Propionate | 14 | $203 | $15 |
| Eszopiclone | 16 | $110 | $7 |
| Zolpidem | 15 | $109 | $7 |
| Trazodone | 20 | $74 | $4 |
2022: 31 drugs
| Trelegy Ellipta | 245 | $227,161 | $927 |
| Ofev | 12 | $152,929 | $12,744 |
| Breo Ellipta | 213 | $148,230 | $696 |
| Symbicort | 83 | $69,746 | $840 |
| Spiriva Handihaler | 58 | $65,685 | $1,133 |
| Advair Diskus | 44 | $40,496 | $920 |
| Spiriva Respimat | 32 | $36,192 | $1,131 |
| Combivent Respimat | 41 | $24,816 | $605 |
| Incruse Ellipta | 38 | $19,529 | $514 |
| Anoro Ellipta | 15 | $12,069 | $805 |
| Eliquis | 20 | $11,162 | $558 |
| Wixela Inhub | 18 | $10,758 | $598 |
| Bevespi Aerosphere | 24 | $10,150 | $423 |
| Montelukast | 433 | $7,727 | $18 |
| Arnuity Ellipta | 14 | $6,374 | $455 |
| Albuterol Sulfate Hfa | 115 | $6,097 | $53 |
| Pulmicort Flexhaler | 11 | $5,215 | $474 |
| Budesonide-Formoterol | 12 | $3,173 | $264 |
| Ventolin Hfa | 34 | $3,106 | $91 |
| Fluticasone-Salmeterol | 12 | $2,214 | $184 |
| Clarithromycin | 52 | $2,138 | $41 |
| Azelastine | 29 | $1,837 | $63 |
| Ipratropium | 37 | $1,166 | $32 |
| Pantoprazole | 22 | $708 | $32 |
| Prednisone | 118 | $551 | $5 |
| Fluticasone Propionate | 20 | $495 | $25 |
| Omeprazole | 44 | $413 | $9 |
| Pramipexole Dihydrochloride | 28 | $378 | $13 |
| Zolpidem | 19 | $110 | $6 |
| Trazodone | 31 | $96 | $3 |
| Eszopiclone | 20 | $55 | $3 |
2021: 33 drugs
| Trelegy Ellipta | 255 | $208,383 | $817 |
| Breo Ellipta | 270 | $162,268 | $601 |
| Ofev | 11 | $134,033 | $12,185 |
| Spiriva | 82 | $89,943 | $1,097 |
| Symbicort | 99 | $85,158 | $860 |
| Spiriva Respimat | 42 | $41,050 | $977 |
| Advair Diskus | 44 | $37,918 | $862 |
| Combivent Respimat | 44 | $27,807 | $632 |
| Incruse Ellipta | 29 | $20,587 | $710 |
| Wixela Inhub | 33 | $18,841 | $571 |
| Anoro Ellipta | 24 | $13,368 | $557 |
| Bevespi Aerosphere | 24 | $10,606 | $442 |
| Sildenafil Citrate | 12 | $10,384 | $865 |
| Montelukast | 466 | $7,762 | $17 |
| Arnuity Ellipta | 18 | $5,903 | $328 |
| Dulera | 11 | $4,912 | $447 |
| Albuterol Sulfate Hfa | 93 | $4,462 | $48 |
| Ventolin Hfa | 28 | $2,526 | $90 |
| Clarithromycin | 21 | $1,729 | $82 |
| Proair Hfa | 12 | $1,057 | $88 |
| Azelastine | 17 | $814 | $48 |
| Ipratropium | 19 | $774 | $41 |
| Pramipexole Dihydrochloride | 41 | $761 | $19 |
| Prednisone | 71 | $515 | $7 |
| Modafinil | 15 | $455 | $30 |
| Fluticasone Propionate | 21 | $303 | $14 |
| Omeprazole | 32 | $287 | $9 |
| Pantoprazole | 12 | $286 | $24 |
| Eszopiclone | 45 | $208 | $5 |
| Zolpidem | 22 | $149 | $7 |
| Alprazolam | 12 | $82 | $7 |
| Famotidine | 16 | $77 | $5 |
| Trazodone | 16 | $55 | $3 |
2020: 26 drugs
| Trelegy Ellipta | 228 | $163,488 | $717 |
| Breo Ellipta | 188 | $116,744 | $621 |
| Spiriva | 68 | $75,463 | $1,110 |
| Symbicort | 86 | $69,119 | $804 |
| Spiriva Respimat | 34 | $31,671 | $931 |
| Advair Diskus | 42 | $27,734 | $660 |
| Incruse Ellipta | 28 | $16,558 | $591 |
| Anoro Ellipta | 27 | $12,151 | $450 |
| Bevespi Aerosphere | 20 | $10,268 | $513 |
| Combivent Respimat | 16 | $10,265 | $642 |
| Wixela Inhub | 25 | $9,736 | $389 |
| Montelukast | 445 | $7,366 | $17 |
| Arnuity Ellipta | 23 | $6,661 | $290 |
| Albuterol Sulfate Hfa | 56 | $2,957 | $53 |
| Ventolin Hfa | 27 | $2,652 | $98 |
| Proair Hfa | 34 | $2,516 | $74 |
| Clarithromycin | 19 | $1,194 | $63 |
| Pramipexole Dihydrochloride | 41 | $747 | $18 |
| Prednisone | 68 | $662 | $10 |
| Azelastine | 15 | $571 | $38 |
| Modafinil | 12 | $395 | $33 |
| Omeprazole | 18 | $307 | $17 |
| Fluticasone Propionate | 15 | $206 | $14 |
| Eszopiclone | 23 | $153 | $7 |
| Zolpidem | 18 | $104 | $6 |
| Sulfamethoxazole-Trimethoprim | 13 | $20 | $2 |
2019: 26 drugs
| Breo Ellipta | 194 | $98,990 | $510 |
| Trelegy Ellipta | 148 | $95,352 | $644 |
| Symbicort | 97 | $75,048 | $774 |
| Spiriva | 64 | $58,965 | $921 |
| Spiriva Respimat | 29 | $28,206 | $973 |
| Advair Diskus | 44 | $25,106 | $571 |
| Combivent Respimat | 26 | $16,561 | $637 |
| Incruse Ellipta | 19 | $15,741 | $828 |
| Montelukast | 522 | $9,896 | $19 |
| Bevespi Aerosphere | 18 | $9,743 | $541 |
| Anoro Ellipta | 22 | $9,304 | $423 |
| Wixela Inhub | 17 | $6,469 | $381 |
| Arnuity Ellipta | 22 | $6,235 | $283 |
| Ventolin Hfa | 38 | $3,081 | $81 |
| Fluticasone-Salmeterol | 13 | $2,395 | $184 |
| Proair Hfa | 19 | $2,180 | $115 |
| Pramipexole Dihydrochloride | 44 | $991 | $23 |
| Clarithromycin | 28 | $973 | $35 |
| Gabapentin | 17 | $737 | $43 |
| Omeprazole | 30 | $495 | $17 |
| Prednisone | 72 | $430 | $6 |
| Modafinil | 15 | $334 | $22 |
| Trazodone | 15 | $177 | $12 |
| Eszopiclone | 17 | $150 | $9 |
| Pantoprazole | 11 | $136 | $12 |
| Furosemide | 22 | $36 | $2 |
2018: 25 drugs
| Spiriva | 88 | $75,333 | $856 |
| Symbicort | 104 | $68,441 | $658 |
| Breo Ellipta | 116 | $51,689 | $446 |
| Advair Diskus | 68 | $43,273 | $636 |
| Trelegy Ellipta | 42 | $31,271 | $745 |
| Spiriva Respimat | 39 | $20,460 | $525 |
| Incruse Ellipta | 23 | $17,690 | $769 |
| Combivent Respimat | 24 | $10,754 | $448 |
| Bevespi Aerosphere | 17 | $10,081 | $593 |
| Sildenafil | 13 | $7,401 | $569 |
| Montelukast | 322 | $6,393 | $20 |
| Proair Hfa | 41 | $4,435 | $108 |
| Ventolin Hfa | 39 | $2,929 | $75 |
| Arnuity Ellipta | 12 | $2,024 | $169 |
| Pramipexole Dihydrochloride | 58 | $1,417 | $24 |
| Azelastine | 14 | $1,268 | $91 |
| Clarithromycin | 18 | $779 | $43 |
| Gabapentin | 24 | $751 | $31 |
| Omeprazole | 24 | $598 | $25 |
| Prednisone | 48 | $252 | $5 |
| Amoxicillin-Clavulanate Potass | 13 | $183 | $14 |
| Pantoprazole | 12 | $178 | $15 |
| Zolpidem | 16 | $136 | $9 |
| Trazodone | 18 | $126 | $7 |
| Eszopiclone | 23 | $106 | $5 |
2017: 23 drugs
| Spiriva | 131 | $86,574 | $661 |
| Symbicort | 156 | $79,606 | $510 |
| Advair Diskus | 73 | $40,848 | $560 |
| Spiriva Respimat | 19 | $12,739 | $670 |
| Breo Ellipta | 33 | $12,525 | $380 |
| Sildenafil | 16 | $12,164 | $760 |
| Armodafinil | 13 | $8,639 | $665 |
| Bevespi Aerosphere | 16 | $7,753 | $485 |
| Incruse Ellipta | 12 | $7,752 | $646 |
| Proair Hfa | 38 | $3,722 | $98 |
| Montelukast | 181 | $3,350 | $19 |
| Ventolin Hfa | 28 | $2,130 | $76 |
| Pramipexole Dihydrochloride | 95 | $1,808 | $19 |
| Clarithromycin | 25 | $822 | $33 |
| Pantoprazole | 28 | $400 | $14 |
| Omeprazole | 27 | $387 | $14 |
| Azithromycin | 23 | $376 | $16 |
| Lorazepam | 20 | $331 | $17 |
| Prednisone | 62 | $228 | $4 |
| Trazodone | 22 | $166 | $8 |
| Eszopiclone | 18 | $100 | $6 |
| Zolpidem | 15 | $79 | $5 |
| Furosemide | 13 | $60 | $5 |
2016: 18 drugs
| Spiriva | 156 | $90,940 | $583 |
| Symbicort | 168 | $83,111 | $495 |
| Advair Diskus | 85 | $41,867 | $493 |
| Sildenafil | 20 | $14,102 | $705 |
| Modafinil | 17 | $7,247 | $426 |
| Proair Hfa | 33 | $3,318 | $101 |
| Montelukast | 144 | $3,237 | $22 |
| Ventolin Hfa | 20 | $1,148 | $57 |
| Pramipexole Dihydrochloride | 70 | $1,026 | $15 |
| Clarithromycin | 12 | $854 | $71 |
| Prednisone | 80 | $699 | $9 |
| Levothyroxine | 15 | $437 | $29 |
| Potassium Chloride | 19 | $429 | $23 |
| Omeprazole | 36 | $336 | $9 |
| Azithromycin | 12 | $191 | $16 |
| Furosemide | 19 | $97 | $5 |
| Amlodipine Besylate | 11 | $82 | $7 |
| Isosorbide Mononitrate Er | 11 | $26 | $2 |
2015: 27 drugs
| Spiriva | 216 | $103,142 | $478 |
| Symbicort | 196 | $81,654 | $417 |
| Advair Diskus | 89 | $38,606 | $434 |
| Sildenafil | 28 | $21,151 | $755 |
| Voriconazole | 13 | $19,588 | $1,507 |
| Foradil | 20 | $5,416 | $271 |
| Modafinil | 16 | $5,397 | $337 |
| Combivent Respimat | 11 | $3,372 | $307 |
| Proair Hfa | 50 | $3,351 | $67 |
| Montelukast | 148 | $3,184 | $22 |
| Daliresp | 12 | $3,070 | $256 |
| Pramipexole Dihydrochloride | 53 | $1,351 | $25 |
| Prednisone | 89 | $666 | $7 |
| Synthroid | 20 | $663 | $33 |
| Omeprazole | 61 | $507 | $8 |
| Azithromycin | 20 | $497 | $25 |
| Levothyroxine | 17 | $431 | $25 |
| Potassium Chloride | 24 | $415 | $17 |
| Levofloxacin | 14 | $289 | $21 |
| Losartan | 14 | $254 | $18 |
| Amlodipine Besylate | 34 | $226 | $7 |
| Simvastatin | 14 | $209 | $15 |
| Warfarin | 19 | $110 | $6 |
| Lisinopril | 17 | $84 | $5 |
| Furosemide | 18 | $73 | $4 |
| Trazodone | 14 | $61 | $4 |
| Sulfamethoxazole-Trimethoprim | 11 | $53 | $5 |
2014: 34 drugs
| Letairis | 27 | $194,331 | $7,197 |
| Spiriva | 279 | $118,010 | $423 |
| Symbicort | 241 | $84,549 | $351 |
| Sildenafil | 57 | $41,667 | $731 |
| Advair Diskus | 86 | $37,442 | $435 |
| Foradil | 33 | $8,734 | $265 |
| Perforomist | 12 | $6,967 | $581 |
| Modafinil | 20 | $6,738 | $337 |
| Daliresp | 23 | $6,152 | $267 |
| Flovent Hfa | 13 | $6,084 | $468 |
| Budesonide | 12 | $5,882 | $490 |
| Proair Hfa | 68 | $4,038 | $59 |
| Nasonex | 15 | $3,830 | $255 |
| Montelukast | 124 | $3,640 | $29 |
| Aggrenox | 11 | $3,600 | $327 |
| Pramipexole Dihydrochloride | 52 | $1,525 | $29 |
| Clarithromycin | 25 | $1,259 | $50 |
| Prednisone | 105 | $982 | $9 |
| Synthroid | 22 | $735 | $33 |
| Omeprazole | 56 | $652 | $12 |
| Potassium Chloride | 28 | $565 | $20 |
| Levofloxacin | 21 | $297 | $14 |
| Amlodipine Besylate | 23 | $225 | $10 |
| Azathioprine | 12 | $219 | $18 |
| Simvastatin | 22 | $212 | $10 |
| Warfarin | 31 | $205 | $7 |
| Verapamil Er | 12 | $187 | $16 |
| Alprazolam | 13 | $174 | $13 |
| Furosemide | 39 | $147 | $4 |
| Cetirizine | 12 | $127 | $11 |
| Zolpidem | 18 | $125 | $7 |
| Sulfamethoxazole-Trimethoprim | 11 | $73 | $7 |
| Lisinopril | 13 | $67 | $5 |
| Temazepam | 11 | $57 | $5 |
2013: 33 drugs
| Letairis | 24 | $162,547 | $6,773 |
| Spiriva | 300 | $110,860 | $370 |
| Symbicort | 206 | $66,062 | $321 |
| Advair Diskus | 72 | $28,634 | $398 |
| Sildenafil | 30 | $26,543 | $885 |
| Modafinil | 21 | $7,868 | $375 |
| Foradil | 17 | $5,786 | $340 |
| Montelukast | 81 | $4,093 | $51 |
| Aggrenox | 13 | $3,520 | $271 |
| Proair Hfa | 45 | $2,402 | $53 |
| Nasonex | 14 | $1,965 | $140 |
| Crestor | 11 | $1,886 | $171 |
| Zolpidem Tartrate Er | 15 | $1,851 | $123 |
| Pramipexole Dihydrochloride | 51 | $1,699 | $33 |
| Omeprazole | 75 | $1,434 | $19 |
| Ventolin Hfa | 12 | $790 | $66 |
| Potassium Chloride | 43 | $665 | $15 |
| Synthroid | 22 | $475 | $22 |
| Prednisone | 91 | $468 | $5 |
| Levofloxacin | 34 | $355 | $10 |
| Azathioprine | 12 | $316 | $26 |
| Simvastatin | 27 | $291 | $11 |
| Warfarin | 31 | $270 | $9 |
| Furosemide | 64 | $224 | $4 |
| Amlodipine Besylate | 14 | $215 | $15 |
| Cetirizine | 11 | $210 | $19 |
| Verapamil Er | 12 | $203 | $17 |
| Losartan | 11 | $170 | $15 |
| Sulfamethoxazole-Trimethoprim | 15 | $123 | $8 |
| Alendronate | 13 | $108 | $8 |
| Zolpidem | 16 | $98 | $6 |
| Glipizide | 12 | $70 | $6 |
| Temazepam | 11 | $69 | $6 |
Money from drug and device companies
$146 in 2024
| 2024 | 1 | 2 | None | $146 |
| 2023 | 3 | 3 | None | $327 |
| 2021 | 2 | 3 | None | $177 |
| 2019 | 3 | 4 | None | $342 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| AstraZeneca Pharmaceuticals LP | Andexxa | $146 | 2 payments
|
See all 2 published payments
| AstraZeneca Pharmaceuticals LP | Meals · 2024-10-16 | Andexxa | $115 |
| AstraZeneca Pharmaceuticals LP | Meals · 2024-10-15 | Andexxa | $31 |
See earlier years (2023, 2021, 2019)
2023: $327
| La Jolla Pharmaceutical | Giapreza | $187 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Saphnelo | $123 | 1 payment
|
| Inspire Medical Systems | Inspire | $17 | 1 payment
|
2021: $177
| NuVasive | Alif | $150 | 1 payment
|
| Electromed | Smartvest | $27 | 2 payments
|
2019: $342
| Portola Pharmaceuticals | Andexxa | $181 | 2 payments
|
| Stryker | Trevo | $140 | 1 payment
|
| GlaxoSmithKline | Trelegy Ellipta | $21 | 1 payment
|
Checkups this office reported
17 measures · 2023
Medicare asked this office to report how often certain checkups happened in 2023. This is not a grade for the doctor. A specialist’s patients may not need every screening.
- Medicare’s overall office score
- 94.9 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
| Appropriate Treatment for Upper Respiratory Infection (URI)As Medicare defines this measure | 100% | 39 |
| Asked about smokingPatients asked about tobacco, with help to quit if they smoke | 87%That's most of the people this applied to. | 1,633 |
| Blood pressure under controlPeople with high blood pressure whose reading was in a healthy range | 63%That's more than half. | 1,128 |
| Bone-density scans that were not neededYounger women who got a bone scan without a medical reason | 1%That's few of the people this applied to. Better on this measure. | 156 |
| Breast cancer screeningEligible women who got a mammogram | 38%That's less than half. | 587 |
| Cervical cancer screeningEligible women who got a Pap or HPV test | 14%That's few of the people this applied to. | 543 |
| Checked for fall riskOlder patients screened for fall risk | 14%That's few of the people this applied to. | 1,226 |
| Colon cancer screeningEligible adults who got a colon cancer test | 26%That's less than half. | 1,560 |
See the other 9 measures
| Depression screeningPatients screened for depression, with a follow-up plan if needed | 8%That's few of the people this applied to. | 2,075 |
| Diabetes eye examPeople with diabetes who got a retinal eye exam | 6%That's few of the people this applied to. | 317 |
| Diabetes poorly controlledPeople with diabetes whose blood sugar stayed very high | 77%That's most of the people this applied to. Worse on this measure. | 317 |
| HIV screeningEligible patients who were screened for HIV | 14%That's few of the people this applied to. | 1,433 |
| Medications listed in the chartVisits where the current medication list was documented | 99%That's most of the people this applied to. | 5,511 |
| Patients can see their records onlinePatients who were given electronic access to their health information | 100%That's most of the people this applied to. | 583 |
| Prescriptions sent electronicallyPrescriptions sent to the pharmacy by computer instead of paper | 98%That's most of the people this applied to. | 368 |
| Statin prescribed when it protects the heartPeople at cardiovascular risk who were prescribed a statin | 81%That's most of the people this applied to. | 958 |
| Weight checked, with a follow-up planPatients whose BMI was recorded and followed up if needed | 38%That's less than half. | 2,538 |
What the office says it does
Boxes the office ticked on its Medicare worksheet for 2023. Nobody checks these.
- Agreed to federal review of their records system
- Did a security review of patient data
- Exchanges records both ways with other health systems
- Improved the patient portal
- Lets patients read their visit notes
- Reports cases to public health electronically
- Shows lab and imaging costs when ordering tests
- Uses standard treatment protocols
- Exempt from immunization registry reporting
- Exempt from query of the prescription drug monitoring program (pdmp)
Professional record
- NPI
- 1922074061
- Licence
- CA A544310
- Trained
- West Virginia University School of Medicine, 1994
- Group
- University Healthcare Alliance · Bass Medical Group
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- Yes
- Medicaid ID
- CA 00A544310
- Taxonomy
- Federal specialty code 207RP1001X (207RP1001X); Internal medicine (207R00000X); Federal specialty code 207RS0012X (207RS0012X); Federal specialty code 2084A2900X (2084A2900X)
- Mailing address
- 2520 Samaritan Dr Ste 104b, San Jose, CA, 95124
- NPI first listed
- 2006-02-28
- NPI last updated
- 2025-03-03
- NPI record certified
- 2025-03-03
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 2425 Samaritan Dr, San Jose, CA, 95124